Compare Oracle Corporation (ORCL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oracle Corporation vs BIO-TECHNE Corp — how do they compare? Oracle Corporation trades at $141.53 (market cap $411.34B), while BIO-TECHNE Corp trades at $72.44 (market cap $11.36B). The key difference: Oracle Corporation is far larger — about 36.2× BIO-TECHNE Corp's market cap, and Oracle Corporation pays the higher dividend (1.47%). Which is the better fit depends on your goals — on Pluang, investors hold Oracle Corporation for 72 Days and BIO-TECHNE Corp for 64 Days on average.
| ORCL | TECH | |
|---|---|---|
Market Cap | $411.34B | $11.36B |
Volume | 41,276,815 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $313.00 | $72.61 |
52-Week Low | $114.99 | $43.31 |
Typical Hold Time | 72 Days | 64 Days |
Enterprise Value | $535.15B | $11.39B |
Dividend Yield | 1.47% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oracle Corporation (ORCL) is trading at $135.56, down 5.58% amid broader market volatility despite strong Q1 2026 earnings that beat expectations with EPS of $2.11 versus $1.96. The stock faces technical bearish signals with support at $133 and resistance at $141, while fundamentals show robust revenue growth to $57.4B in 2025 and net income margin expansion to 26.36%. Recent AI-driven infrastructure investments and layoffs highlight strategic shifts to capitalize on cloud demand.
Oracle's outlook remains positive with analyst consensus price target of $236.52 implying 74% upside, supported by 65% buy ratings. Key opportunities include AI cloud revenue growth accelerating 120% in Q1 2026, though risks persist from high debt levels ($85.3B long-term) and sensitivity to Fed policy given the stock's 1.9 beta. Investors should weigh strong profitability against execution risks in aggressive data center expansion.
TECH trades at $72.46, near its 52-week high of $72.70, with a slight daily decline of 0.1%. The stock shows a bullish technical signal from moving averages, while oscillators are neutral. Recent earnings have been mixed, with a Q2 2026 beat but a Q1 miss. The company maintains strong gross margins of 65.77%, though net income margin has compressed to 14.97% in 2025 from 24.6% in 2022. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The pending acquisition at $73.00 offers a clear near-term upside of about 0.7% from the current price, limiting downside risk. However, execution risks remain until deal closure, and profitability pressures pose concerns for standalone operations. Analyst consensus is divided with 46% Buy and 54% Hold ratings, reflecting cautious optimism amid transition uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
